Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors

5 May 2023

Abstract excerpt

BACKGROUND: Triple-negative breast cancer (TNBC) is a subtype of breast cancer with limited treatment options and poor clinical prognosis. Inhibitors of transcriptional CDKs are currently under thorough investigation for application in the treatment of multiple cancer types, including breast cancer. These studies have raised interest in combining these inhibitors, including CDK12/13 inhibitor THZ531, with a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Cancer-related Molecular Pathways
Share to Drug Transport and Resistance Mechanisms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37147730
DOI: 10.1186/s13058-023-01648-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitorsPMID 37147730Read ↗

Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast CancerSemantic proximity Read ↗

Functional genomics identifies new synergistic therapies for retinoblastomaSemantic proximity Read ↗

Targeting Mutated p53 Dependency in Triple-Negative Breast Cancer Cells Through CDK7 InhibitionSemantic proximity Read ↗

Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast CancerSemantic proximity Read ↗

BOGO: A Proteome-Wide Gene Overexpression Platform for Discovering Rational Cancer Combination TherapiesSemantic proximity Read ↗

Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast CancerSemantic proximity Read ↗

Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancersSemantic proximity Read ↗

CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinomaSemantic proximity Read ↗

Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in NeuroblastomaSemantic proximity Read ↗

Cooperative regulation of coupled oncoprotein synthesis and stability in triple-negative breast cancer by EGFR and CDK12/13Semantic proximity Read ↗

A Synergistic Anti-Cancer FAK and HDAC Inhibitor Combination Discovered by a Novel Chemical-Genetic High-Content Phenotypic ScreenSemantic proximity Read ↗

MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.